ReviewInternational journal of molecular sciences2025

Sodium-Glucose Transporter-2 Inhibitors (SGLT2i) and Myocardial Ischemia: Another Compelling Reason to Consider These Agents Regardless of Diabetes.

Francesco Piccirillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.